Revolution Medicines (RVMD) Stock Forecast & Price Target

Revolution Medicines is viewed positively because its lead RAS inhibitor, Rasonque, has already shown transformational efficacy in 2L PDAC and now has a full approval supported by randomized phase III OS benefit, creating a meaningful commercial moat versus competitors relying on earlier endpoints. The company’s pipeline is also unusually deep, with Phase 3 programs in NSCLC, PDAC, and adjuvant PDAC, while mutant-specific assets like zoldonrasib and elironrasib expand the addressable market and support modeled peak sales of $21.2B, $10.5B, and $2.1B. Management also sees improving economics from earlier EU revenue, lower royalty burden, and strong capital to fund commercialization, reinforcing long-term revenue potential toward $16B+ peak sales.

Revolution Medicines is facing a mixed but ultimately cautious fundamental backdrop because its early VS-7375 data are encouraging in KRAS G12D PDAC, yet the results come from a very small patient population and do not establish durable competitive superiority. In KRAS G12 NSCLC, VS-7375 underperformed zoldonrasib in both 1L combination therapy, with a 75% ORR in 8 patients versus 82%, and 2L+ monotherapy, with a 43% ORR in 23 patients versus 52%, raising questions about differentiation. Although a 900 mg dose may improve efficacy, the mention of a worse safety profile suggests the company may need to trade off potency and tolerability, which is a key risk for a clinical-stage oncology developer.